Literature DB >> 17685886

Novel uses for risperidone: focus on depressive, anxiety and behavioral disorders.

Arun V Ravindran1, Cheryl Bradbury, Martha McKay, Tricia L da Silva.   

Abstract

Risperidone has been shown to be a safe and effective atypical antipsychotic agent. It was initially approved for the treatment of schizophrenia, and now, in many countries, is used to treat other conditions, including bipolar disorder, dementia and behavior problems in a range of age groups. Yet, frequent off-label use by clinicians to treat other mood and anxiety disorders and behavioral disorders is common and requires an examination of the risks and benefits in such populations. A review of the literature provides varying levels of evidence supporting its use in a range of depressive and anxiety disorders, and in special populations, including children and the elderly. Most reports are based on short-term studies and include its use both as monotherapy and as an augmenting agent to other psychotropics, and in a range of doses. Further randomized controlled trials are needed to confirm the efficacy and tolerability of risperidone, both short- and long-term, in many of these conditions. The published evidence is summarized, with recommendations and suggestions for its use.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17685886     DOI: 10.1517/14656566.8.11.1693

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  5 in total

1.  Population pharmacokinetics of oral risperidone in children, adolescents and adults with psychiatric disorders.

Authors:  An Thyssen; An Vermeulen; Eliane Fuseau; Marc-Antoine Fabre; Erik Mannaert
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

2.  Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.

Authors:  L Eugene Arnold; Kenneth D Gadow; Cristan A Farmer; Robert L Findling; Oscar Bukstein; Brooke S G Molina; Nicole V Brown; Xiaobai Li; E Victoria Rundberg-Rivera; Srihari Bangalore; Kristin Buchan-Page; Elizabeth A Hurt; Robert Rice; Nora K McNamara; Michael G Aman
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-04       Impact factor: 2.576

3.  "Attenuated psychosis syndrome" or "subthreshold prodromal state"?

Authors:  Vassilis Kontaxakis; Beata Havaki-Kontaxaki; Konstantinos Kollias; Panagiotis Ferentinos; George Papadimitriou
Journal:  Psychiatry Investig       Date:  2013-05-30       Impact factor: 2.505

4.  Risperidone, quetiapine, and olanzapine adjunctive treatments in major depression with psychotic features: a comparative study.

Authors:  A Gabriel
Journal:  Neuropsychiatr Dis Treat       Date:  2013-04-12       Impact factor: 2.570

Review 5.  Efficacy of amisulpride for depressive symptoms in individuals with mental disorders: A systematic review and meta-analysis.

Authors:  Caroline Zangani; Barbara Giordano; Hans-Christian Stein; Stefano Bonora; Armando D'Agostino; Edoardo Giuseppe Ostinelli
Journal:  Hum Psychopharmacol       Date:  2021-06-03       Impact factor: 1.672

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.